Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden

J. E. Johansson, L. Holmberg, S. Johansson, R. Bergstrom and H. O. Adami
Department of Urology, Orebro Medical Centre, Orebro, Sweden.

OBJECTIVE: To describe the natural history of initially untreated early-stage prostate cancer. A key secondary objective was to calculate long-term survival rates by stage, grade, and age at diagnosis. DESIGN: Prospective cohort study. SETTING: Population-based in 1 county of Sweden, without screening for prostate cancer. PATIENTS: A group of 642 patients with prostate cancer of any stage, consecutively diagnosed between 1977 and 1984 at a mean age of 72 years with complete follow-up to 1994. MAIN OUTCOME MEASURES: Proportion of patients who died from prostate cancer, and 15-year survival (with 95% confidence interval [CI]), corrected for causes of death other than prostate cancer. RESULTS: In the entire cohort, prostate cancer accounted for 201 (37%) of all 541 deaths. Among 300 patients with a diagnosis of localized disease (T0-T2), 33 (11%) died of prostate cancer. In this group, the corrected 15-year survival rate was similar in 223 patients with deferred treatment (81%; 95% CI, 72%-89%) and in 77 who received initial treatment (81%; 95% CI, 67%-95%). The corrected 15-year survival was 57% (95% CI, 45%-68%) in 183 patients with locally advanced cancer (T3-T4) and 6% (95% CI, 0%-12%) in those 159 who had distant metastases at the time of diagnosis. CONCLUSION: Patients with localized prostate cancer have a favorable outlook following watchful waiting, and the number of deaths potentially avoidable by radical initial treatment is limited. Without reliable prognostic indicators, an aggressive approach to all patients with early disease would entail substantial overtreatment. In contrast, patients with locally advanced or metastatic disease need trials of aggressive therapy to improve their poor prognosis.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Functional MR Imaging of Prostate Cancer
Choi et al.
RadioGraphics 2007;27:63-75.
ABSTRACT | FULL TEXT  

Active Surveillance for Prostate Cancer: For Whom?
Klotz
JCO 2005;23:8165-8169.
ABSTRACT | FULL TEXT  

Radical Prostatectomy versus Watchful Waiting in Early Prostate Cancer
Bill-Axelson et al.
NEJM 2005;352:1977-1984.
ABSTRACT | FULL TEXT  

Natural History of Early Localized Prostate Cancer
Osborn and Chodak
JAMA 2004;292:1549-1549.
FULL TEXT  

Pretreatment Evaluation of Prostate Cancer: Role of MR Imaging and 1H MR Spectroscopy
Claus et al.
RadioGraphics 2004;24:S167-S180.
ABSTRACT | FULL TEXT  

Identification of Clinically Significant Prostate Cancer by Prostate-Specific Antigen Screening
Smith et al.
Arch Intern Med 2004;164:1227-1230.
ABSTRACT | FULL TEXT  

Natural History of Early, Localized Prostate Cancer
Johansson et al.
JAMA 2004;291:2713-2719.
ABSTRACT | FULL TEXT  

Waiting Time in Prostate Cancer
Neugut and Grann
JAMA 2004;291:2757-2758.
FULL TEXT  

Masculine Vitality: Pros and Cons of Testosterone in Treating the Andropause
Asthana et al.
J. Gerontol. A Biol. Sci. Med. Sci. 2004;59:M461-M465.
FULL TEXT  

Prostate-Specific Antigen Screening in Elderly Men
Lu-Yao et al.
JNCI J Natl Cancer Inst 2003;95:1792-1797.
ABSTRACT | FULL TEXT  

Temporarily Deferred Therapy (watchful waiting) for Men Younger Than 70 Years and With Low-Risk Localized Prostate Cancer in the Prostate-Specific Antigen Era
Carter et al.
JCO 2003;21:4001-4008.
ABSTRACT | FULL TEXT  

Why do Primary Care Physicians in the United States and France Order Prostate-Specific Antigen Tests for Asymptomatic Patients?
Sorum et al.
Med Decis Making 2003;23:301-313.
ABSTRACT  

Management of High-Risk Populations with Locally Advanced Prostate Cancer
Khan and Partin
The Oncologist 2003;8:259-269.
ABSTRACT | FULL TEXT  

Watchful Waiting as a Treatment Option for Localized Prostate Cancer in the PSA Era
Kakehi
Jpn J Clin Oncol 2003;33:1-5.
ABSTRACT | FULL TEXT  

Screening for Prostate Cancer: An Update of the Evidence for the U.S. Preventive Services Task Force
Harris and Lohr
ANN INTERN MED 2002;137:917-929.
ABSTRACT | FULL TEXT  

Cancer Survival Among US Whites and Minorities: A SEER (Surveillance, Epidemiology, and End Results) Program Population-Based Study
Clegg et al.
Arch Intern Med 2002;162:1985-1993.
ABSTRACT | FULL TEXT  

Aberrant Promoter Methylation Profile of Prostate Cancers and Its Relationship to Clinicopathological Features
Maruyama et al.
Clin. Cancer Res. 2002;8:514-519.
ABSTRACT | FULL TEXT  

Prostate Cancer: Contrast-enhanced US for Detection
Halpern et al.
Radiology 2001;219:219-225.
ABSTRACT | FULL TEXT  

The clinical burden of prostate cancer in Canada: forecasts from the Montreal Prostate Cancer Model
Grover et al.
CMAJ 2000;162:977-983.
ABSTRACT | FULL TEXT  

The economic burden of prostate cancer in Canada: forecasts from the Montreal Prostate Cancer Model
Grover et al.
CMAJ 2000;162:987-992.
ABSTRACT | FULL TEXT  

Treatment of Locally Advanced Prostate Cancer: Is Chemotherapy the Next Step?
Oh and Kantoff
JCO 1999;17:3664-3675.
ABSTRACT | FULL TEXT  

Prostate Cancer Practice Patterns and Quality of Life: the Prostate Cancer Outcomes Study
Potosky et al.
JNCI J Natl Cancer Inst 1999;91:1719-1724.
FULL TEXT  

Geriatrics and the Limits of Modern Medicine
Goodwin
NEJM 1999;340:1283-1285.
FULL TEXT  

RESPONSES - Re: Trends in Reported Incidence of Primary Malignant Brain Tumors in Children in the United States
Black
JNCI J Natl Cancer Inst 1999;91:648a-649a.
FULL TEXT  

Competing Risk Analysis of Men Aged 55 to 74 Years at Diagnosis Managed Conservatively for Clinically Localized Prostate Cancer
Albertsen et al.
JAMA 1998;280:975-980.
ABSTRACT | FULL TEXT  

Detection of Prostate and Colon Cancer
Stern et al.
JAMA 1998;280:117-118.
FULL TEXT  

FIFTEEN-YEAR OUTLOOK GOOD FOR PATIENTS WITH LOCALIZED PROSTATE CANCER
JWatch General 1997;1997:1-1.
FULL TEXT